<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Oncol</journal-id><journal-id journal-id-type="publisher-id">JO</journal-id><journal-title>Journal of Oncology</journal-title><issn pub-type="ppub">1687-8450</issn><issn pub-type="epub">1687-8469</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19259333</article-id><article-id pub-id-type="pmc">2648631</article-id><article-id pub-id-type="doi">10.1155/2008/741310</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>CYP1A1, mEH, and GSTM1 Polymophisms and Risk of Oral and Pharyngeal Cancer: A Spanish Case-Control Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Varela-Lema</surname><given-names>L.</given-names></name><xref ref-type="aff" rid="I1"><sup>1,2</sup></xref><xref ref-type="aff" rid="I2"/></contrib><contrib contrib-type="author"><name><surname>Ruano-Ravina</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="I1"><sup>1,2,3</sup></xref><xref ref-type="aff" rid="I2"/><xref ref-type="aff" rid="I3"/><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Juiz Crespo</surname><given-names>M. A.</given-names></name><xref ref-type="aff" rid="I4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kelsey</surname><given-names>K. T.</given-names></name><xref ref-type="aff" rid="I5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Loidi</surname><given-names>L.</given-names></name><xref ref-type="aff" rid="I6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Barros-Dios</surname><given-names>J. M.</given-names></name><xref ref-type="aff" rid="I1"><sup>1,3,6</sup></xref><xref ref-type="aff" rid="I3"/><xref ref-type="aff" rid="I6"/></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Preventive Medicine and Public Health, University of Santiago de Compostela, 15782 Santiago de Compostela, Galicia, Spain</aff><aff id="I2"><sup>2</sup>Galician Agency for Health Technology Assessment, Galician Health Service, 15782 Santiago de Compostela, Galicia, Spain</aff><aff id="I3"><sup>3</sup>Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), 08003 Barcelona, Spain</aff><aff id="I4"><sup>4</sup>Centro de Sa&#x000fa;de Porto do Son, 15970 A Coru&#x000f1;a, Spain</aff><aff id="I5"><sup>5</sup>Department of Genetics and Complex Diseases, Harvard School of Public Health, MA 02115, USA</aff><aff id="I6"><sup>6</sup>Unit of Molecular Medicine, Santiago de Compostela University Hospital, Galician Health Service, 15706 Santiago de Compostela, Galicia, Spain</aff><author-notes><corresp id="cor1">*A. Ruano-Ravina: <email>mralbert@usc.es</email></corresp><fn fn-type="other"><p>Recommended by Youcef M. Rustum</p></fn></author-notes><pub-date pub-type="ppub"><year>2008</year></pub-date><pub-date pub-type="epub"><day>22</day><month>9</month><year>2008</year></pub-date><volume>2008</volume><elocation-id>741310</elocation-id><history><date date-type="received"><day>21</day><month>5</month><year>2008</year></date><date date-type="accepted"><day>22</day><month>7</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 L. Varela-Lema et al.</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>					<italic>Background</italic>. Genetic polymorphisms of drug metabolizing enzymes involved in the detoxification pathways of carcinogenic substances may influence cancer risk. <italic>Methods</italic>. Case-control study that investigates the relationship between CYP1A1 Ile/Val, exon 4 mEH, and GSTM1 null genetic polymorphism and the risk of oral and pharyngeal cancer examining the interaction between these genes, tobacco, and alcohol. 92 incident cases and 130 consecutive hospital-based controls have been included. <italic>Results</italic>. No significant associations were found for any of the genotypes assessed. The estimated risk was slightly elevated in subjects with the wild type of the mEH gene and the null GSTM1 genotype. For exon 4 mEH heterozygous polymorphism, the risk was slightly lower for heavy smokers than for light smokers. The inverse association was observed for the GSTM1 null genotype. <italic>Conclusions</italic>. The results suggest that exon 4 mEH and GSTM1 null polymorphisms might influence oral and pharyngeal cancer.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. Introduction</title><p>Oral and pharyngealcancers represent an important problem worldwide. The incidence and prevalencerates for these tumors are double in men than in women. Cancers of the oralcavity rank as the eighth most common cancer among men, being responsible for3% of the cancers diagnosed in this gender [<xref ref-type="bibr" rid="B1">1</xref>]. Mortality rates aresubstantially lower than incidence rates. According to the World HealthOrganization (WHO) data, the standardized mortality rate for 2002 was 2.2deaths per 100 000 population.</p><p>Tobacco and alcoholare the main risk factors for oral and pharyngeal cancers. In USA and Europe,they are responsible for 75&#x02013;80% of thesetumors [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>]. Epidemiologic studies performed in all continents have found anincreased risk in smokers, which seems to rise with daily consumption andduration [<xref ref-type="bibr" rid="B4">4</xref>&#x02013;<xref ref-type="bibr" rid="B7">7</xref>]. There is alsosufficient evidence to conclude that excessive consumption of alcoholicbeverages is associated with oral and pharyngeal cancers, causing in some cases risks higher than those found for smokers [<xref ref-type="bibr" rid="B8">8</xref>&#x02013;<xref ref-type="bibr" rid="B10">10</xref>].</p><p>The reason why someindividuals develop cancer and others do not can be attributed, at least partly,to variations in genetic polymorphisms responsible for metabolizingcarcinogenic substances found in tobacco and alcohol. Although many genes havebeen associated with metabolism of these compounds, some with the highestrational of those beinginvolved are CYP1A1, mEH, and GSTM1.</p><p>The CYP1A1 genebelongs to the CYP1 subfamily and encodes for the enzyme aryl hydrocarbonhydrolase, which is involved in the activation of many polycyclic aromatichydrocarbons and aromatic amines [<xref ref-type="bibr" rid="B11">11</xref>] and is present in oral tissue [<xref ref-type="bibr" rid="B12">12</xref>]. Thisenzyme is implicated in the metabolism of benzo[a]pyrene, a potent tobaccocarcinogen. Various studies have shown that CYP1A1 catalyzes the initialconversion of benzo[a]pyrene to 7,8 dihydrodiol-9,10-oxide [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>]. Two CYP1A1polymorphisms have been related to different tumors, including head and neckcancers. One of these is a single-base substitution of adenine to guanine atposition 2455 in the heme-binding region of exon 7, which induces an amino acid change inisoleucine to valine at codon 462, known as the Ile/Val or exon 7 polymorphism(Ile 462 Val) or CYP1A1*2C. This mutation has also been referred to as mutationm2. The Ile/Ile genotype corresponds to the wild type, and Ile-Val and Val-Valto the heterozygous and homozygous genotypes for the mutant allele,respectively [<xref ref-type="bibr" rid="B15">15</xref>]. This mutation is rare in Caucasians, and is in completelinkage disequilibrium with the CYP1A1 MspI mutation (CYP1A1*2B) [<xref ref-type="bibr" rid="B16">16</xref>].</p><p>The microsomal formof epoxide hydrolase is primarily associated with the metabolism of exogenousxenobiotic compounds. Its interest in oral and pharyngeal cancers comes fromthe fact that it has been detected in alltissues including the aerodigestive tract and catalyzes the hydrolosis of arene, alkene, and aliphatic epoxides frompolycyclic aromatic hydrocarbons and aromatic amines [<xref ref-type="bibr" rid="B17">17</xref>]. Enzymatically, mEH catalyzes the hydrolysis ofepoxides to trans-dihydrodiols [<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B19">19</xref>]. Two polymorphisms in the mEH gene have been reported [<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>]. The first polymorphism is produced as aconsequence of a substitution of C &#x02192; Twithin exon 3 of the gene and results in a substitution of His to Tyr in amino acidposition 113. This polymorphism is known as the &#x0201c;slow allele&#x0201d; since in vitrostudies show a 40&#x02013;60% decrease inenzyme activity in comparison to the wild type. This allele is also known asHYL*2. In the second polymorphism, G substitutes A in exon 4, leading to anemplacement of histidine for arginine in the amino acid position 139 (139 Arg &#x02192; His). This polymorphism is known as the fast allele HYL*3since it produces a 25% increase in enzyme activity in vitro. Tyr is thepredominant amino acid at the 113 position in Caucasian populations, and His isthe most predominant at position 139.</p><p>The glutathione Stransferase (GST) comprises a family of phase II detoxifying enzymes thatcatalyze a great number of detoxification reactions that take place between thecytosolic glutathione and compounds containing an electrofilic centre [<xref ref-type="bibr" rid="B22">22</xref>]. TheGST substrates include acetaldehyde and several polycyclic aromatichydrocarbons found in tobacco smoke. The GSTM1 is involved in thedetoxification of benzo[a]pyrene-7,8-diol-9,10-oxide [<xref ref-type="bibr" rid="B23">23</xref>]. Metabolism of thiscarcinogen involves a balance between the activation steps mediated by theepoxide hydrolase and the cytochrome system and the detoxification steps,involving GSTM1, that inhibit the activity of the DNA binding intermediates andcatalyze the conversion of the reactive electrophiles to inactive, water-solubleconjugates that can be easily removed [<xref ref-type="bibr" rid="B13">13</xref>]. Even though frequencies of GSTM1null genotypes vary among different ethnic groups, in white Caucasians, it isdeleted in approximately 50% of the population [<xref ref-type="bibr" rid="B24">24</xref>&#x02013;<xref ref-type="bibr" rid="B33">33</xref>].</p><p>In the present case-controlstudy, we aimed to examine the relationship between the CYP1A1 Ile/Val, exon 4 mEH(139 Arg &#x02192; His), and GSTM1 nullgenetic polymorphism and the risk of oral and pharyngeal cancers, investigatingalso the association with smoking, drinking, and the gene-gene interactions.</p></sec><sec sec-type="section" id="sec2"><title>2. Patients and Methods</title><sec id="subsec2.1"><title>2.1. Design, Subjects, and Settings</title><p>The presenthospital-based case-control study was conducted at the Santiago de CompostelaUniversity Hospital Complex (Galicia,NW Spain) between January 1996 and January 2000. Data was collected on a totalof 92 incident Caucasian male cases with histopathologically confirmeddiagnosis of primary oral or pharyngeal cancers. The study was restricted tonewly diagnosed patients over 20 years of age without a prior history ofcancer. For study purposes, tumors of the lip were excluded.</p><p>A total of 130 consecutivecontrols were included from patients attending the Hospital ComplexPreoperative Unit for nonsmoking- and nonalcohol-related trivial surgery. Theinclusion criterion for controls was absence of prior history of cancer. Subjectsunder 20 years of age were excluded. The types of surgical procedures controls were scheduled to undergo mainlycomprised inguinal hernias, cataracts, and orthopedic surgery. Informed consentwas obtained from all study subjects prior to the interview and the extractionof total blood. Only 1 case and 6 controls refused to participate in the study. The study protocol was approved by the Galician Ethical Research Committee.</p></sec><sec id="subsec2.2"><title>2.2. Information Retrieval</title><p>All study subjectswere interviewed by a person purpose-trained to administer a structuredquestionnaire addressing various aspects of lifestyle, with special emphasis onsmoking habit, alcohol consumption, occupation, and other activities related to the development oforal and pharyngeal cancers. For cases, the interview was done as soon aspossible after cancer was detected and always within 15 days from diagnosis. The questionnaire used was previously applied to a group of individualsfulfilling the characteristics of the subjects going to be included and allquestions with difficult interpretation were duly amended.</p></sec><sec id="subsec2.3"><title>2.3. Laboratory Methods</title><p>After cases andcontrols were identified, whole blood samples of 6 mL were collected from eachsubject in heparin-containing tubes. The samples were stored at 4&#x000b0;C and centrifuged at 2800 rpmfor at least 10 minutes within the next 24 hours. The three independentfractions were isolated and stored at &#x02212;84&#x000b0;C until analysis. DNA was extracted fromthe buffy coat of middle layer containing monocytes. The cells were washed withTE (10x) and centrifuged at 3000 rpm during 10 minutes several times until theywere cleaned. The pellet was then treated with lysis buffer and proteinase K in1% SDS previous to the extraction of DNA with phenol-chloroform and ethanolprecipitation similarly as previously described [<xref ref-type="bibr" rid="B34">34</xref>]. The DNA was precipitated in the presence of highconcentrations of ammonium acetate (to further purify the DNA) and resuspendedin TE to approximately 300 <italic>&#x003bc;</italic>g/mL. The genotypingassays were performed at the Molecular Medicine Unit of the Santiago deCompostela University Hospital Complex.</p><p>Genotyping for GSTM1was carried out in the whole sample using a modified PCR method describedpreviously [<xref ref-type="bibr" rid="B35">35</xref>]. Reactions were carried out in a final volume of 12.5 <italic>&#x003bc;</italic>L containing 20 mM Tris-HCl (PH 8.4), 50 mM KCl, 3 mM MgCl<sub>2</sub>, 0.25 <italic>&#x003bc;</italic>Mof each GSTM1 primer, 0.25 <italic>&#x003bc;</italic>M of each <italic>&#x003b2;</italic>-globin primer (internal control), 1 U Taq DNApolymerase (Promega), 2 <italic>&#x003bc;</italic>Meach dNTPs, and 600&#x02013;900 ng of DNA. The GSTM1 primers were 5&#x02032;-GAACTCCCTGAAAAGCTAAGC and 5&#x02032;-GTTGGGCTCAAATATACGGTGG.  A negative control was included in allbatches. The PCR conditions were 94&#x000b0; for 3 minutes, followed by 35 cyclesof  94&#x000b0;C for 30 seconds, 58&#x000b0;C for 30 seconds, 72&#x000b0;C for 45 seconds, and afinal extension of 72&#x000b0;C for 7 minutes.</p><p>To analyse the exon4 mEH polymorphism (EH<sup>139 arg</sup>), a 357-bp fragment containing thepolymorphic site was amplified [<xref ref-type="bibr" rid="B36">36</xref>]. The PCR was performed in all subjectsusing the sense primer 5&#x02032;-GGGGTGCCAGAGCCTGACCGT-3&#x02032; and the antisense primer5&#x02032;-AACACCGGGCCCACCCTTGGC-3&#x02032; (Sigma-Genosys). The PCR cycling conditions were 95&#x000b0;C for 2 minutes, followed by 35 cycles at 95&#x000b0;C for 30 seconds, 60&#x000b0;C for 30 seconds, 72&#x000b0;C for 30 seconds, with afinal step at 72&#x000b0;C for 7 minutes. After PCR amplification, 10 <italic>&#x003bc;</italic>L ofthe PCR product was digested overnight at 37&#x000b0;C with 10U of RsaI (Invitrogen). The wild-typegenotype (AA) produced 295-bp and 62-bp bands, the heterozygous genotype (AG)yielded 295-bp, 174-bp, 121-bp, 62-bp; and the rare allele (GG) gave 174-bp,121-bp, and 62-bp bands.</p><p>The Ile-Valpolymorphism was analysed in only 158 of the 222 individuals included using an allele-specificoligonucleotide-PCR procedure previously described by Hayashi et al. [<xref ref-type="bibr" rid="B16">16</xref>]. Inthe same reaction mix, two primers with different terminal bases (1A1A or 1A1G),which contained the polymorphic site at the 3&#x02032;end, were added (1A1G :5&#x02032;-GAACTGCCACTTCAGCTGTCT-3&#x02032; and 1A1A : 5&#x02032;-AAGACCTCCCAGCGGGCAAT-3&#x02032;) inconjunction with another strand of primer (1A1.1 : 5&#x02032;-GAACTGCCACTTCAGCTGTCT-3&#x02032;). Two amplification reactions were necessary for each one of the subjects analysed,one with the primers 1A1.1/1A1A which recognize the Ile462 allele and anotherwith the primers 1A1.1/1A1G which recognize the Val462 allele. PCR was carriedout at 30 cycles under the following conditions: 30 seconds at 95&#x000b0; fordenaturing, 1 minute at 60&#x000b0;C for primer annealing, and 1 minute at 72&#x000b0;C for primer extension.</p><p>All the productswere electrophoresed on a 2% agarose gel stained with ethidium bromide andvisualized under UV light. To test for eventual contamination, negativecontrols were introduced in each run.</p></sec><sec id="subsec2.4"><title>2.4. Statistical Analysis</title><p>Logistic regressionwas employed to analyse the effect of each of the genes studied. The wild typegene was considered as the reference category for each gene in each analysis. All the regressions were adjusted for age, tobacco consumption in pack-years,and alcohol consumption in grams/week. For analyzing the effect of thedifferent polymorphisms across different categories of tobacco and alcoholconsumption, the cutpoint was established on the median creating twocategories, low and high consumption in order to achieve a higher statisticalpower. In all analyses, the dependent variable was the status of case orcontrol and the risks were expressed as ORs with CI 95%. All the analyses wereperformed with SPSS 11.5 statistical package.</p></sec></sec><sec sec-type="section" id="sec3"><title>3. Results</title><p>The study populationcovered a total of 222 subjects, comprising 92 cases and 130 controls. Adescription of the sample characteristics is presented in <xref ref-type="table" rid="tab1">Table 1</xref>. The mean ageof the controls (59.4 years; CI 95% 57&#x02013;61.8) wasslightly higher than that of cases (55 years; CI 95% 52.7&#x02013;57.3). The 57.6% ofthe tumors were located in the oral cavity (tongue 27, oral floor 7, palate 6, andother parts 12) and 96.7% were squamous cell carcinomas. Smoking and alcoholconsumption were morefrequent among cancer cases than controls. A percentage of 98% of the caseswere smokers and 46.7% of these (<italic>n</italic> = 43) were considered as heavy drinkers (morethan six glasses of wine/beers or two liquors a day), whilst in the controlgroup 62% of the individuals smoked and 10.8% (<italic>n</italic> = 14) were heavy drinkers.</p><p>The frequency ofGSTM1 null genotype was 51.1% among oral and pharyngeal cancer patients and 47.7%among controls. The exon 4 mEH (139 Arg &#x02192; His) heterozygouspolymorphism (His/Arg) was present in 31.5% of the control group and in 27.2%of the case group. Only 4 subjects (4.3%) in the case group and 1 subject inthe control group (0.8%) presented homozygous mutations. There were nodifferences in the frequency of mutations for the CYP1A1 exon 7 polymorphism. The mutant alleles (Ile/Val, Val/Val) were observed in only 2 cases (3%) and 2controls (2.2%).</p><p>				<xref ref-type="table" rid="tab2">Table 2</xref> shows the oddsratio estimates for combined oral and pharyngeal cancers associated with the GSTM1,CYP1A1, and exon 4 mEH polymorphisms. To determine the effect of thesepolymorphisms on different cancer sites, oral cavity and pharyngeal tumors wereevaluated separately. No statistically significant effect was observed for anyof the polymorphisms studied for any of the anatomic subtypes. The limitednumber of subjects with mutant CYP1A1 alleles did not allow for a calculationof the OR for oral cavity tumors.</p><p>To assess dose-responserelationship, we have calculated pack-years of smoking (1 pack (20cigarettes/day)   &#x000d7;   years of smoking). Smokers were classified as non-to-light/moderatesmokers (&#x02264;35 pack-years) and heavy smokers (&#x0003e;35 pack-years). Non smokers were analysedtogether with light/moderate smokers because there were only 2 nonsmokers amongthe cases and this did not allow for a separate analysis. The odds ratios associatedwith tobacco consumption by the different genotypes analysed are shown in <xref ref-type="table" rid="tab3">Table 3</xref>. This analysis was not performed for CYP1A1 due to the limited number of patientswith mutated alleles and the same happened for alcohol consumption. For the His/Arggenotype of exon 4 mEH, it could be observed that the risk was slightly lowerfor heavy smokers (OR 0.68; 95% CI 0.25&#x02013;1.86) than forlight smokers (OR 1.08; 95% CI 0.37&#x02013;3.13) but theassociations were not significant for any of the categories of tobaccoconsumption. The GSTM1 null genotype revealed an inverse pattern, showing an ORof 0.88 (95% CI 0.34&#x02013;2.34) for lightsmokers and an OR of 1.40 (95% CI 0.57&#x02013;3.43) for heavysmokers.</p><p>To examine the interaction between these genotypes andthe drinking status, we carried out a second stratification analysis. Twocategories of alcohol consumption were established. Those that consumed 280 gm/weekof alcohol or less (&#x02264;2glasses of wine/beers or 2 liquors a day) were considered as light drinkers,and those that exceeded those values as heavy drinkers. Once again, due to thelow number of nondrinkers among the cases (<italic>n</italic> = 2), these subjects were analysedin combination with light drinkers. The risks for the two different categoriesof alcohol consumption, light and heavy drinkers, are displayed in <xref ref-type="table" rid="tab4">Table 4</xref>. There seems to be a very slight nonsignificant negative association for the His/Arggenotype of exon 4 mEH for both categories of alcohol consumption. The GSTM1gene has a different effect, with its absence posing a slightly higher associationfor light drinkers (OR 1.97% CI 0.73&#x02013;5.35) than for moderate/heavydrinkers (OR 0.69; 95% CI 0.28&#x02013;1.72).</p><p>The interactionbetween mEH and GSTM1 genes is shown in <xref ref-type="table" rid="tab5">Table 5</xref>. No significant effect wasdetected for the interaction although the estimated risk was higher for thosesubjects with the wild-type mEH gene and the null GSTM1 genotype (OR 1.45; 95%CI 0.66&#x02013;3.17). There wasno any apparent effect when both genes were mutated or absent (OR 1.07; 95% CI0.39&#x02013;2.92).</p></sec><sec sec-type="section" id="sec4"><title>4. Discussion</title><p>Even though previousstudies have been undertaken to examine the association between CYP1A1 Ile/Val,mEH, and GSTM1 null polymorphisms, as well as oral and pharyngeal cancers, fewinvestigated the modification of risk associated with tobacco and alcoholconsumption, and to our knowledge, this is the first to analyse the gene-geneinteractions between these polymorphisms. Our results support the view that there is no significant associationfor any of these polymorphisms in Caucasians but our data suggest that exon 4 mEH (139 Arg &#x02192; His) and GSTM1 nullpolymorphism might modify the risk related to tobacco and alcohol consumption.</p><p>We observed that theexon mEH polymorphism 139 Arg &#x02192; His was mutatedin a very similar proportion in cases and controls and the frequencies found (32,3%in controls versus 31,5% in cases) were consistent with the results of theprevious investigations that assessed the association between this polymorphismin head and neck tumors in both sexes [<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B37">37</xref>&#x02013;<xref ref-type="bibr" rid="B41">41</xref>]. In thesestudies, mutated alleles were present in 29.7&#x02013;39.8% of thecontrol population and in 28.9&#x02013;39% of the cancerpatients. In the present analysis, the estimated risks were not significant for any of thetobacco or alcohol consumption levels but the results were in agreement withthose of Wenghoefer et al. [<xref ref-type="bibr" rid="B37">37</xref>] that showed that the heterozygous allele (His/Arg)of exon 4 mEH could modulate the risk of head and neck cancer in smokers (OR 0.57;CI 95% 0.34&#x02013;0.95). In ourstudy, the risk was lower in heavy smokers (OR 0.68; 95% CI 0.25&#x02013;1.86) than inlight smokers (OR 1.08; 95% CI 0.37&#x02013;3.13) but notsignificant, maybe influenced by the small sample size.</p><p>Enzymaticaly, mEHcatalyzes the hydrolysis of arene, alkene, andaliphatic epoxides from polycyclic aromatic hydrocarbons and aromatic amines totrans-dihydrodiols [<xref ref-type="bibr" rid="B19">19</xref>]. This reaction is usually regarded as a detoxifyingpathway because the majority of metabolites produced are less reactive and canbe easily excreted, but, in some instances, these initial trans-dihydrodiolmetabolites can be further activated by subsequent P450 catalysis to formhighly carcinogenic electrofilic intermediates that can bind covalently to DNA. Such is the case of the 7,8-diol-9,10-epoxide, which is more carcinogenic thanthe other benzo[a]pyrene diol epoxide formed [<xref ref-type="bibr" rid="B42">42</xref>]. Whilst the results of somestudies, including the present one, are compatible with the fact that a high orintermediate activity might exert a protective effect in subjects exposed totobacco products [<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B44">44</xref>], others carried out in variousaerodigestive tract cancers find no association or a significantly higher riskfor smokers with the exon 4 mEH variant allele [<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B39">39</xref>]; reasons forthese inconsistencies are unclear. It could be argued that high activity shouldbe assessed taking into account both the exon 3 and exon 4 mEH polymorphisms. Some authors predicted mEH activity aslow, intermediate, or high based on the presence or absence of the twopolymorphisms but the results are also contradictory [<xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B46">46</xref>]. Thestudy undertaken by Wenghoefer et al. [<xref ref-type="bibr" rid="B37">37</xref>] found an association for the singlegenotypes in head and neck cancers but not the combination genotypes, raisinguncertainties in categorizing enzymes. Given thedual role of mEH on the bioactivation/detoxification of carcinogens, it ishighly probable that other polymorphisms might influence the formation ofcarcinogenic metabolites and that gene-gene interactions might exist. In thisinvestigation, we did not find a significant interaction between the GSTM1 and exon4 mEH polymorphism.</p><p>The frequency of theGSTM1 null allele polymorphisms in oral and pharyngealcancers has been reported to vary greatly depending on the geographical regions[<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B48">48</xref>]. Whilst in Europe and USA  the frequencies reported in control populations range from around 49&#x02013;55.6% [<xref ref-type="bibr" rid="B24">24</xref>&#x02013;<xref ref-type="bibr" rid="B32">32</xref>] in Asian andSouth American countries, this allele is frequently present in less than 49% ofthe control subjects [<xref ref-type="bibr" rid="B49">49</xref>&#x02013;<xref ref-type="bibr" rid="B60">60</xref>]. In thepresent study, 47.7% of the control population presented the GSTM1 nullpolymorphism. This is slightly lower than the values found in other Caucasianstudies and could be partly due to the fact that only males were included. Ourstudy, like other previous reports on Caucasians [<xref ref-type="bibr" rid="B24">24</xref>&#x02013;<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B28">28</xref>&#x02013;<xref ref-type="bibr" rid="B32">32</xref>], failed tofind a significant association between the GSTM1 null polymorphism and oral andpharyngeal cancers.Several studies undertaken in Asian populations showed contradictory results [<xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B56">56</xref>&#x02013;<xref ref-type="bibr" rid="B60">60</xref>]. In a veryrecent meta- and pooled analysis, it was observed that the GSTM1 nullpolymorphism was significantly associated with risk in Asian andAfrican-American populations in the meta- (OR 1.5; 95% CI 1.3&#x02013;1.8) and pooled(adjusted OR 2.4, 95% CI 1.1&#x02013;5.5) analysis,respectively, but not in Caucasians [<xref ref-type="bibr" rid="B48">48</xref>]. This discrepancy might be attributed to differences inlifestyle, environmental risk factors, and variations in the activity of other metabolizingenzymes, which often displaysgenetic polymorphisms that might differ in Caucasians and in other ethnicgroups [<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B59">59</xref>, <xref ref-type="bibr" rid="B61">61</xref>].</p><p>We did not find asignificant interaction between the GSTM1 null polymorphism and tobacco smoking,but we did observe that the risk was slightly higher in heavy smokers than inlight/moderate smokers. To verify that these differences were not due to thefact that nonsmokers were analysed together with light/moderate smokers, wecarried out a separate analysis leaving out these subjects and found that thevariations in the odds ratios were minimum (data not shown). It has been hypothesisedthat lack of GSTM1 enzyme activity increases cancer susceptibility as a resultof a decreased ability to detoxify reactive intermediates of tobaccocarcinogens such as benzo[a]pyrene-7,8-diol epoxide, the activated form ofbenzo[a]pyrene [<xref ref-type="bibr" rid="B22">22</xref>] but the results of previous studies undertaken in oral andpharyngeal cancers are inconsistent [<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B54">54</xref>, <xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B57">57</xref>]. Some authors find a lowerdifference in risk among the genotypes at high dose levels and suggest adose-response relationship of the enzymatic reaction [<xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B57">57</xref>]. In the presentstudy, the relationship between tobacco exposure and these polymorphisms isdifficult to assess because there were only 2 nonsmokers among the cases and 6 subjectsthat smoked for less than 20 years, forcing us to create a category that waslight/moderate smokers. Studies with larger number of patients are needed toproperly assess this dose response relationship taking into account that ethnicand geographical differences might exist due to the different forms of tobaccoconsumption and diet intake. In Asian and South Americancountries, tobacco is usually smoked as &#x0201c;bidis&#x0201d; and the carcinogenic substancesfound in this form of preparation are different to that in cigarettes, implyingthat other enzymes different thanGSTM1 and CYP1A1 might be involved in the detoxification [<xref ref-type="bibr" rid="B28">28</xref>].</p><p>Our study suggeststhat the effect of the GSTM1 null polymorphism is more noticeable among lightdrinkers, although this association was nonsignificant. This relationship wasmaintained when we took out the nondrinkers from the analysis (data not shown). This differential effect could be explained by the fact that the GSTM1isoenzyme, together with the alcohol dehydrogenase, is involved in theoxidation of ethanol to acetaldehyde [<xref ref-type="bibr" rid="B30">30</xref>]. Even though the exact mechanisms bywhich ethanol may exert an influence in oral cancer is still unknown, it hasbeen suggested that acetaldehyde, a known carcinogenic agent, [<xref ref-type="bibr" rid="B62">62</xref>] could beresponsible for some DNA changes that could lead to cancer [<xref ref-type="bibr" rid="B63">63</xref>]. Individualswith a null GSTM1 and high drinkers would not convert ethanol in acetaldehydeand then the absence of the gene would confer them a protective effect fororopharyngeal cancer. Another explanation for these finding could be thatethanol increases the permeability of tobacco carcinogens, such asnitrosonornicotine, across the oral membrane when it is present at lowconcentrations. At concentrations higher than 50%, no further permeabilizationis noted, probably due to the fixative effect of ethanol on the mucosa [<xref ref-type="bibr" rid="B64">64</xref>]. Itshould be highlighted that the alcohol consumption in the Galician population isvery high, as other studies have reported [<xref ref-type="bibr" rid="B65">65</xref>], and this is a limitation that doesnot allow for a proper analysis of the interaction.</p><p>Even though theCYP1A1 mutation has been shown to increase microsomal activity for convertingprocarcinogens, including PAH aromatic amines, the results of various reportson smoking-related cancers are inconsistent [<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B66">66</xref>&#x02013;<xref ref-type="bibr" rid="B70">70</xref>]. It hasbeen suggested that the DNA damage may depend on the link of CYP1A1 to otherpolymorphisms that can affect the CYP1A1 transcription levels, such aspolymorphisms for promoter genes, AHR (Ah receptor) genes, or metabolic genessuch as GSTM1 [<xref ref-type="bibr" rid="B69">69</xref>, <xref ref-type="bibr" rid="B70">70</xref>]. In our study, only 4 of the analysed subjects showed anIle/Val mutation. Although these frequencies are in accordance with those foundby Hahn et al. in a Caucasian population [<xref ref-type="bibr" rid="B25">25</xref>], it made it impossible to drawany conclusion for this polymorphism. Confidence intervals obtained were verywide and the distribution of this polymorphism was very similar between casesand controls. In any case, neither the previous meta- and pooled analysis onCYP1A1 and risk of head and neck cancer [<xref ref-type="bibr" rid="B47">47</xref>] nor the recently published metaand pooled analysis on oral and pharyngeal cancer founda significant association between  CYP1A1(Ile/Val) polymorphism and oral and pharyngeal cancer [<xref ref-type="bibr" rid="B48">48</xref>].</p><p>This paper hasseveral limitations. The main one is the small sample size included. This is especiallyimportant when analyzing polymorphisms that have a very low frequency in thepopulation, such as CYP1A1 Ile/Val, but also limits the power to identifygene-environmental and gene-gene interactions in any polymorphismsinvestigated. Nevertheless, it has to be taken into account that for cancerswith a low incidence such as oral and pharyngeal ones, 92 cases can be arelatively good number. Another limitation could be the fact that our study washospital-based and this could result in selection bias. Even though it has beensuggested that studies with hospital controls can provide lower risk estimates,since diseases of controls could be associated with the polymorphisms understudy, previous meta- and pooled analysis that assessed these polymorphisms onhead and neck cancers found no differences for hospital-based studies inrelation to population-based studies [<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B66">66</xref>]. The fact that not all the samplewas analysed for CYP1A1 polymorphisms limited the power to detect a significantrisk.</p><p>The present studyhas also some advantages. One of them is that the participation of cases andcontrols was very high. All the cases belonged to the same catchment area,which has a unique reference hospital, and were collected consecutively, makingthem representative of the cases in that area. The controls also belonged tothe same area and did not have any symptom or disease related to alcohol or tobaccoconsumption. Another advantage is the fact that the genes analysed here were ofphase I and phase II, which adds value to the results obtained. When studyingsusceptibility genes in many occasions, both types of genes are not studied andindividuals can have susceptibility in type I compensated with the activity of the other type suchas it was shown in  Park et al. investigation [<xref ref-type="bibr" rid="B29">29</xref>].</p><p>As a conclusion, itseems that even though none of the three genotypes analysed have a significantassociation with the risk of oral and pharyngeal cancer in this population, therisks of tobacco and alcohol consumption might be modified by GSTM1 null andexon 4 mEH polymorphisms. The small number of nonsmoking and nondrinking subjectsin our population limited our analysis, so we propose that further studies are carriedout to clarify this question. Even though we found no significant interactionbetween the GSTM1null genotype and the exon 4 mEH genotype, the GSTM1 absencedid show a slight rise in risk so this should also be investigated taking intoaccount other polymorphisms including the CYP1A1.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was funded by the Galician Regional Research Authority (XUGA 208001B93). Part of this work has been done while the secondauthor was doing a research stay at the Harvard School of Public Health.</p></ack><ref-list><ref id="B1"><label>1</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Pisani</surname><given-names>P</given-names></name><name><surname>Parkin</surname><given-names>DM</given-names></name></person-group><source><italic>GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide</italic></source><year>2004</year><publisher-loc>Lyon, France</publisher-loc><publisher-name>IARC Press</publisher-name><series>IARC CancerBase no. 5</series></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blot</surname><given-names>WJ</given-names></name><name><surname>McLaughlin</surname><given-names>JK</given-names></name><name><surname>Winn</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Smoking and drinking in relation to oral and pharyngeal cancer</article-title><source><italic>Cancer Research</italic></source><year>1988</year><volume>48</volume><issue>11</issue><fpage>3282</fpage><lpage>3287</lpage><pub-id pub-id-type="pmid">3365707</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Castellsagu&#x000e9;</surname><given-names>X</given-names></name><name><surname>Quintana</surname><given-names>MJ</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>MC</given-names></name><etal/></person-group><article-title>The role of type of tobacco and type of alcoholic beverage in oral carcinogenesis</article-title><source><italic>International Journal of Cancer</italic></source><year>2004</year><volume>108</volume><issue>5</issue><fpage>741</fpage><lpage>749</lpage></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Franceschi</surname><given-names>S</given-names></name><name><surname>Talamini</surname><given-names>R</given-names></name><name><surname>Barra</surname><given-names>S</given-names></name><etal/></person-group><article-title>Smoking and drinking in relation to cancers of the oral cavity, pharynx, larynx, and esophagus in Northern Italy</article-title><source><italic>Cancer Research</italic></source><year>1990</year><volume>50</volume><issue>20</issue><fpage>6502</fpage><lpage>6507</lpage><pub-id pub-id-type="pmid">2208109</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lissowska</surname><given-names>J</given-names></name><name><surname>Pilarska</surname><given-names>A</given-names></name><name><surname>Pilarski</surname><given-names>P</given-names></name><etal/></person-group><article-title>Smoking, alcohol, diet, dentition and sexual practices in the epidemiology of oral cancer in Poland</article-title><source><italic>European Journal of Cancer Prevention</italic></source><year>2003</year><volume>12</volume><issue>1</issue><fpage>25</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">12548107</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moreno-L&#x000f3;pez</surname><given-names>LA</given-names></name><name><surname>Esparza-G&#x000f3;mez</surname><given-names>GC</given-names></name><name><surname>Gonz&#x000e1;lez-Navarro</surname><given-names>A</given-names></name><name><surname>Cerero-Lapiedra</surname><given-names>R</given-names></name><name><surname>Gonz&#x000e1;lez-Hern&#x000e1;ndez</surname><given-names>MJ</given-names></name><name><surname>Dom&#x000ed;nguez-Rojas</surname><given-names>V</given-names></name></person-group><article-title>Risk of oral cancer associated with tobacco smoking, alcohol consumption and oral hygiene: a case-control study in Madrid, Spain</article-title><source><italic>Oral Oncology</italic></source><year>2000</year><volume>36</volume><issue>2</issue><fpage>170</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">10745168</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosenquist</surname><given-names>K</given-names></name></person-group><article-title>Risk factors in oral and oropharyngeal squamous cell carcinoma: a population-based case-control study in southern Sweden</article-title><source><italic>Swedish Sental Journal. Supplement</italic></source><year>2005</year><issue>179</issue><fpage>1</fpage><lpage>66</lpage></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bundgaard</surname><given-names>T</given-names></name><name><surname>Wildt</surname><given-names>J</given-names></name><name><surname>Frydenberg</surname><given-names>M</given-names></name><name><surname>Elbrond</surname><given-names>O</given-names></name><name><surname>Nielsen</surname><given-names>JE</given-names></name></person-group><article-title>Case-control study of squamous cell cancer of the oral cavity in Denmark</article-title><source><italic>Cancer Causes and Control</italic></source><year>1995</year><volume>6</volume><issue>1</issue><fpage>57</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">7718736</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>La Vecchia</surname><given-names>C</given-names></name><name><surname>Franceschi</surname><given-names>S</given-names></name><name><surname>Favero</surname><given-names>A</given-names></name><name><surname>Talamini</surname><given-names>R</given-names></name><name><surname>Negri</surname><given-names>E</given-names></name></person-group><article-title>Alcohol intake and cancer of the upper digestive tract. Pattern of risk in Italy is different from that in Denmark</article-title><source><italic>British Medical Journal</italic></source><year>1999</year><volume>318</volume><issue>7193</issue><fpage>1289</fpage><lpage>1291</lpage><pub-id pub-id-type="pmid">10231282</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gr&#x000f8;nb&#x000e6;k</surname><given-names>M</given-names></name><name><surname>Becker</surname><given-names>U</given-names></name><name><surname>Johansen</surname><given-names>D</given-names></name><name><surname>T&#x000f8;nnesen</surname><given-names>H</given-names></name><name><surname>Jensen</surname><given-names>G</given-names></name><name><surname>S&#x000f8;rensen</surname><given-names>TIA</given-names></name></person-group><article-title>Population based cohort study of the association between alcohol intake and cancer of the upper digestive tract</article-title><source><italic>British Medical Journal</italic></source><year>1998</year><volume>317</volume><issue>7162</issue><fpage>844</fpage><lpage>848</lpage><pub-id pub-id-type="pmid">9748175</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bartsch</surname><given-names>H</given-names></name><name><surname>Nair</surname><given-names>U</given-names></name><name><surname>Risch</surname><given-names>A</given-names></name><name><surname>Rojas</surname><given-names>M</given-names></name><name><surname>Wikman</surname><given-names>H</given-names></name><name><surname>Alexandrov</surname><given-names>K</given-names></name></person-group><article-title>Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers</article-title><source><italic>Cancer Epidemiology Biomarkers &#x00026; Prevention</italic></source><year>2000</year><volume>9</volume><issue>1</issue><fpage>3</fpage><lpage>28</lpage></citation></ref><ref id="B12"><label>12</label><citation citation-type="confproc"><person-group person-group-type="author"><name><surname>Romkes</surname><given-names>M</given-names></name><name><surname>White</surname><given-names>C</given-names></name><name><surname>Johnson</surname><given-names>J</given-names></name><name><surname>Eibling</surname><given-names>D</given-names></name><name><surname>Landreneau</surname><given-names>R</given-names></name><name><surname>Branch</surname><given-names>R</given-names></name></person-group><article-title>Expression of cytochrome P450 mRNA in human lung, head and neck tumors and normal adjacent tissues</article-title><conf-name>In: Proceedings of the 87th Annual Meeting of the American Association for Cancer Research (AACR '96), vol. 37</conf-name><conf-date>April 1996</conf-date><conf-loc>Washington, DC, USA</conf-loc><fpage>105</fpage></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shimada</surname><given-names>T</given-names></name><name><surname>Martin</surname><given-names>MV</given-names></name><name><surname>Pruess-Schwartz</surname><given-names>D</given-names></name><name><surname>Marnett</surname><given-names>LJ</given-names></name><name><surname>Guengerich</surname><given-names>FP</given-names></name></person-group><article-title>Roles of individual human cytochrome P-450 enzymes in the bioactivation of benzo(<italic>a</italic>)pyrene, 7,8-dihydroxy-7,8-dihydrobenzo(<italic>a</italic>)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons</article-title><source><italic>Cancer Research</italic></source><year>1989</year><volume>49</volume><issue>22</issue><fpage>6304</fpage><lpage>6312</lpage><pub-id pub-id-type="pmid">2509067</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quan</surname><given-names>T</given-names></name><name><surname>Reiners</surname><given-names>JJ</given-names><suffix>Jr.</suffix></name><name><surname>Bell</surname><given-names>AO</given-names></name><name><surname>Hong</surname><given-names>N</given-names></name><name><surname>States</surname><given-names>JC</given-names></name></person-group><article-title>Cytotoxicity and genotoxicity of (&#x000b1;)-benzo[<italic>a</italic>]pyrene-<italic>trans</italic>-7,8-dihydrodiol in CYP1A1-expressing human fibroblasts quantitatively correlate with CYP1A1 expression level</article-title><source><italic>Carcinogenesis</italic></source><year>1994</year><volume>15</volume><issue>9</issue><fpage>1827</fpage><lpage>1832</lpage><pub-id pub-id-type="pmid">7923575</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Kawakiri</surname><given-names>K</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Vineis</surname><given-names>P</given-names></name><name><surname>Malats</surname><given-names>N</given-names></name><name><surname>Lang</surname><given-names>M</given-names></name><etal/></person-group><article-title>CYP1A1</article-title><source><italic>Metabolic Polymorphisms and Susceptibility to Cancer</italic></source><year>1999</year><volume>148</volume><publisher-loc>Lyon, France</publisher-loc><publisher-name>IARC Scientific Publications no. 148</publisher-name><fpage>173</fpage><lpage>195</lpage></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>S</given-names></name><name><surname>Watanabe</surname><given-names>J</given-names></name><name><surname>Nakachi</surname><given-names>K</given-names></name><name><surname>Kawajiri</surname><given-names>K</given-names></name></person-group><article-title>Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene</article-title><source><italic>The Journal of Biochemistry</italic></source><year>1991</year><volume>110</volume><issue>3</issue><fpage>407</fpage><lpage>411</lpage></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guengerich</surname><given-names>FP</given-names></name></person-group><article-title>Epoxide hydrolase: properties and metabolic roles</article-title><source><italic>Reviews in Biochemical Toxicology</italic></source><year>1982</year><volume>4</volume><fpage>5</fpage><lpage>30</lpage></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beetham</surname><given-names>JK</given-names></name><name><surname>Grant</surname><given-names>D</given-names></name><name><surname>Arand</surname><given-names>M</given-names></name><etal/></person-group><article-title>Gene evolution of epoxide hydrolases and recommended nomenclature</article-title><source><italic>DNA and Cell Biology</italic></source><year>1995</year><volume>14</volume><issue>1</issue><fpage>61</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">7832993</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fretland</surname><given-names>AJ</given-names></name><name><surname>Omiecinski</surname><given-names>CJ</given-names></name></person-group><article-title>Epoxide hydrolases: biochemistry and molecular biology</article-title><source><italic>Chemico-Biological Interactions</italic></source><year>2000</year><volume>129</volume><issue>1-2</issue><fpage>41</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">11154734</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hassett</surname><given-names>C</given-names></name><name><surname>Robinson</surname><given-names>KB</given-names></name><name><surname>Beck</surname><given-names>NB</given-names></name><name><surname>Omiecinski</surname><given-names>CJ</given-names></name></person-group><article-title>The human microsomal epoxide hydrolase gene (EPHX1): complete nucleotide sequence and structural characterization</article-title><source><italic>Genomics</italic></source><year>1994</year><volume>23</volume><issue>2</issue><fpage>433</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">7835893</pub-id></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hassett</surname><given-names>C</given-names></name><name><surname>Aicher</surname><given-names>L</given-names></name><name><surname>Sidhu</surname><given-names>JS</given-names></name><name><surname>Omiecinski</surname><given-names>CJ</given-names></name></person-group><article-title>Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants</article-title><source><italic>Human Molecular Genetics</italic></source><year>1994</year><volume>3</volume><issue>3</issue><fpage>421</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">7516776</pub-id></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>JD</given-names></name><name><surname>Pulford</surname><given-names>DJ</given-names></name></person-group><article-title>The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance</article-title><source><italic>Critical Reviews in Biochemistry and Molecular Biology</italic></source><year>1995</year><volume>30</volume><issue>6</issue><fpage>445</fpage><lpage>600</lpage><pub-id pub-id-type="pmid">8770536</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coles</surname><given-names>B</given-names></name><name><surname>Ketterer</surname><given-names>B</given-names></name></person-group><article-title>The role of glutathione and glutathione transferases in chemical cardnogenesis</article-title><source><italic>Critical Reviews in Biochemistry and Molecular Biology</italic></source><year>1990</year><volume>25</volume><issue>1</issue><fpage>47</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">2182291</pub-id></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gronau</surname><given-names>S</given-names></name><name><surname>Koenig-Greger</surname><given-names>D</given-names></name><name><surname>Jerg</surname><given-names>M</given-names></name><name><surname>Riechelmann</surname><given-names>H</given-names></name></person-group><article-title>GSTM1 enzyme concentration and enzyme activity in correlation to the genotype of detoxification enzymes in squamous cell carcinoma of the oral cavity</article-title><source><italic>Oral Diseases</italic></source><year>2003</year><volume>9</volume><issue>2</issue><fpage>62</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">12657030</pub-id></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>M</given-names></name><name><surname>Hagedorn</surname><given-names>G</given-names></name><name><surname>Kuhlisch</surname><given-names>E</given-names></name><name><surname>Schackert</surname><given-names>HK</given-names></name><name><surname>Eckelt</surname><given-names>U</given-names></name></person-group><article-title>Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to oral cavity cancer</article-title><source><italic>Oral Oncology</italic></source><year>2002</year><volume>38</volume><issue>5</issue><fpage>486</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">12110344</pub-id></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jourenkova-Mironova</surname><given-names>N</given-names></name><name><surname>Voho</surname><given-names>A</given-names></name><name><surname>Bouchardy</surname><given-names>C</given-names></name><etal/></person-group><article-title>Glutathione <italic>S</italic>-transferase <italic>GSTM1, GSTM3, GSTP1</italic> and <italic>GSTT1</italic> genotypes and the risk of smoking-related oral and pharyngeal cancers</article-title><source><italic>International Journal of Cancer</italic></source><year>1999</year><volume>81</volume><issue>1</issue><fpage>44</fpage><lpage>48</lpage></citation></ref><ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nazar-Stewart</surname><given-names>V</given-names></name><name><surname>Vaughan</surname><given-names>TL</given-names></name><name><surname>Burt</surname><given-names>RD</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Berwick</surname><given-names>M</given-names></name><name><surname>Swanson</surname><given-names>GM</given-names></name></person-group><article-title>Glutathione <italic>S</italic>-transferase M1 and susceptibility to nasopharyngeal carcinoma</article-title><source><italic>Cancer Epidemiology Biomarkers &#x00026; Prevention</italic></source><year>1999</year><volume>8</volume><issue>6</issue><fpage>547</fpage><lpage>551</lpage></citation></ref><ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matthias</surname><given-names>C</given-names></name><name><surname>Bockm&#x000fc;hl</surname><given-names>U</given-names></name><name><surname>Jahnke</surname><given-names>V</given-names></name><etal/></person-group><article-title>Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers</article-title><source><italic>Pharmacogenetics</italic></source><year>1998</year><volume>8</volume><issue>2</issue><fpage>91</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">10022746</pub-id></citation></ref><ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Muscat</surname><given-names>JE</given-names></name><name><surname>Ren</surname><given-names>Q</given-names></name><etal/></person-group><article-title>						<italic>CYP1A1</italic> and <italic>GSTM1</italic> polymorphisms and oral cancer risk</article-title><source><italic>Cancer Epidemiology Biomarkers &#x00026; Prevention</italic></source><year>1997</year><volume>6</volume><issue>10</issue><fpage>791</fpage><lpage>797</lpage></citation></ref><ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coutelle</surname><given-names>C</given-names></name><name><surname>Ward</surname><given-names>PJ</given-names></name><name><surname>Fleury</surname><given-names>B</given-names></name><etal/></person-group><article-title>Laryngeal and oropharyngeal cancer, and alcohol dehydrogenase 3 and glutathione S-transferase M1 polymorphisms</article-title><source><italic>Human Genetics</italic></source><year>1997</year><volume>99</volume><issue>3</issue><fpage>319</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">9050916</pub-id></citation></ref><ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deakin</surname><given-names>M</given-names></name><name><surname>Elder</surname><given-names>J</given-names></name><name><surname>Hendrickse</surname><given-names>C</given-names></name><etal/></person-group><article-title>Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers</article-title><source><italic>Carcinogenesis</italic></source><year>1996</year><volume>17</volume><issue>4</issue><fpage>881</fpage><lpage>884</lpage><pub-id pub-id-type="pmid">8625505</pub-id></citation></ref><ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boccia</surname><given-names>S</given-names></name><name><surname>Cadoni</surname><given-names>G</given-names></name><name><surname>Sayed-Tabatabaei</surname><given-names>FA</given-names></name><etal/></person-group><article-title>						<italic>CYP1A1, CYP2E1, GSTM1, GSTT1, EPHX1</italic> exons 3 and 4, and <italic>NAT2</italic> polymorphisms, smoking, consumption of alcohol and fruit and vegetables and risk of head and neck cancer</article-title><source><italic>Journal of Cancer Research and Clinical Oncology</italic></source><year>2008</year><volume>134</volume><issue>1</issue><fpage>93</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">17611777</pub-id></citation></ref><ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzen</surname><given-names>HS</given-names></name><name><surname>Guvenc</surname><given-names>G</given-names></name><name><surname>Turanli</surname><given-names>M</given-names></name><name><surname>Comert</surname><given-names>E</given-names></name><name><surname>Duydu</surname><given-names>Y</given-names></name><name><surname>Elhan</surname><given-names>A</given-names></name></person-group><article-title>The role of GSTM1 and GSTT1 polymorphisms in head and neck cancer risk</article-title><source><italic>Oncology Research</italic></source><year>2007</year><volume>16</volume><issue>9</issue><fpage>423</fpage><lpage>429</lpage><pub-id pub-id-type="pmid">18074677</pub-id></citation></ref><ref id="B34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Olshan</surname><given-names>AF</given-names></name><name><surname>Weissler</surname><given-names>MC</given-names></name><name><surname>Watson</surname><given-names>MA</given-names></name><name><surname>Bell</surname><given-names>DA</given-names></name></person-group><article-title>						<italic>GSTM1, GSTT1, GSTP1, CYP1A1</italic>, and <italic>NAT1</italic> polymorphisms, tobacco use, and the risk of head and neck cancer</article-title><source><italic>Cancer Epidemiology Biomarkers &#x00026; Prevention</italic></source><year>2000</year><volume>9</volume><issue>2</issue><fpage>185</fpage><lpage>191</lpage></citation></ref><ref id="B35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>DA</given-names></name><name><surname>Taylor</surname><given-names>JA</given-names></name><name><surname>Paulson</surname><given-names>DF</given-names></name><name><surname>Robertson</surname><given-names>CN</given-names></name><name><surname>Mohler</surname><given-names>JL</given-names></name><name><surname>Lucier</surname><given-names>GW</given-names></name></person-group><article-title>Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer</article-title><source><italic>Journal of the National Cancer Institute</italic></source><year>1993</year><volume>85</volume><issue>14</issue><fpage>1159</fpage><lpage>1164</lpage><pub-id pub-id-type="pmid">8320745</pub-id></citation></ref><ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Spitz</surname><given-names>MR</given-names></name><name><surname>Gwyn</surname><given-names>KM</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name></person-group><article-title>Microsomal epoxide hydrolase polymorphisms and lung cancer risk in non-hispanic whites</article-title><source><italic>Molecular Carcinogenesis</italic></source><year>2002</year><volume>33</volume><issue>2</issue><fpage>99</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">11813302</pub-id></citation></ref><ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wenghoefer</surname><given-names>M</given-names></name><name><surname>Pesch</surname><given-names>B</given-names></name><name><surname>Harth</surname><given-names>V</given-names></name><etal/></person-group><article-title>Association between head and neck cancer and microsomal epoxide hydrolase genotypes</article-title><source><italic>Archives of Toxicology</italic></source><year>2003</year><volume>77</volume><issue>1</issue><fpage>37</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">12491039</pub-id></citation></ref><ref id="B38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lacko</surname><given-names>M</given-names></name><name><surname>Roelofs</surname><given-names>HMJ</given-names></name><name><surname>te Morsche</surname><given-names>RHM</given-names></name><etal/></person-group><article-title>Microsomal epoxide hydrolase genotypes and the risk for head and neck cancer</article-title><source><italic>Head &#x00026; Neck</italic></source><year>2008</year><volume>30</volume><issue>7</issue><fpage>836</fpage><lpage>844</lpage><pub-id pub-id-type="pmid">18383527</pub-id></citation></ref><ref id="B39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>To-Figueras</surname><given-names>J</given-names></name><name><surname>Gen&#x000e9;</surname><given-names>M</given-names></name><name><surname>G&#x000f3;mez-Catal&#x000e1;n</surname><given-names>J</given-names></name><etal/></person-group><article-title>Microsomal epoxide hydrolase and glutathione S-transferase polymorphisms in relation to laryngeal carcinoma risk</article-title><source><italic>Cancer Letters</italic></source><year>2002</year><volume>187</volume><issue>1-2</issue><fpage>95</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">12359356</pub-id></citation></ref><ref id="B40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jourenkova-Mironova</surname><given-names>N</given-names></name><name><surname>Mitrunen</surname><given-names>K</given-names></name><name><surname>Bouchardy</surname><given-names>C</given-names></name><name><surname>Dayer</surname><given-names>P</given-names></name><name><surname>Benhamou</surname><given-names>S</given-names></name><name><surname>Hirvonen</surname><given-names>A</given-names></name></person-group><article-title>High-activity microsomal epoxide hydrolase genotypes and the risk of oral, pharynx, and larynx cancers</article-title><source><italic>Cancer Research</italic></source><year>2000</year><volume>60</volume><issue>3</issue><fpage>534</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">10676631</pub-id></citation></ref><ref id="B41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Schantz</surname><given-names>SP</given-names></name><name><surname>Lazarus</surname><given-names>P</given-names></name></person-group><article-title>Epoxide hydrolase genotype and orolaryngeal cancer risk: interaction with GSTM1 genotype</article-title><source><italic>Oral Oncology</italic></source><year>2003</year><volume>39</volume><issue>5</issue><fpage>483</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">12747973</pub-id></citation></ref><ref id="B42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shou</surname><given-names>M</given-names></name><name><surname>Gonzalez</surname><given-names>FJ</given-names></name><name><surname>Gelboin</surname><given-names>HV</given-names></name></person-group><article-title>Stereoselective epoxidation and hydration at the K-region of polycyclic aromatic hydrocarbons by cDNA-expressed cytochromes P450 1A1, 1A2, and epoxide hydrolase</article-title><source><italic>Biochemistry</italic></source><year>1996</year><volume>35</volume><issue>49</issue><fpage>15807</fpage><lpage>15813</lpage><pub-id pub-id-type="pmid">8961944</pub-id></citation></ref><ref id="B43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heckbert</surname><given-names>SR</given-names></name><name><surname>Weiss</surname><given-names>NS</given-names></name><name><surname>Hornung</surname><given-names>SK</given-names></name><name><surname>Eaton</surname><given-names>DL</given-names></name><name><surname>Motulsky</surname><given-names>AG</given-names></name></person-group><article-title>Glutathione S-transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers</article-title><source><italic>Journal of the National Cancer Institute</italic></source><year>1992</year><volume>84</volume><issue>6</issue><fpage>414</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">1538419</pub-id></citation></ref><ref id="B44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amador</surname><given-names>AG</given-names></name><name><surname>Righi</surname><given-names>PD</given-names></name><name><surname>Radpour</surname><given-names>S</given-names></name><etal/></person-group><article-title>Polymorphisms of xenobiotic metabolizing genes in oropharyngeal carcinoma</article-title><source><italic>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, &#x00026; Endodontics</italic></source><year>2002</year><volume>93</volume><issue>4</issue><fpage>440</fpage><lpage>445</lpage></citation></ref><ref id="B45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kiyohara</surname><given-names>C</given-names></name><name><surname>Yoshimasu</surname><given-names>K</given-names></name><name><surname>Takayama</surname><given-names>K</given-names></name><name><surname>Nakanishi</surname><given-names>Y</given-names></name></person-group><article-title>EPHX1 polymorphisms and the risk of lung cancer: a HuGE review</article-title><source><italic>Epidemiology</italic></source><year>2006</year><volume>17</volume><issue>1</issue><fpage>89</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">16357600</pub-id></citation></ref><ref id="B46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>WJ</given-names></name><name><surname>Brennan</surname><given-names>P</given-names></name><name><surname>Boffetta</surname><given-names>P</given-names></name><etal/></person-group><article-title>Microsomal epoxide hydrolase polymorphisms and lung cancer risk: a quantitative review</article-title><source><italic>Biomarkers</italic></source><year>2002</year><volume>7</volume><issue>3</issue><fpage>230</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">12141066</pub-id></citation></ref><ref id="B47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hashibe</surname><given-names>M</given-names></name><name><surname>Brennan</surname><given-names>P</given-names></name><name><surname>Strange</surname><given-names>RC</given-names></name><etal/></person-group><article-title>Meta- and pooled analysis of <italic>GSTM1, GSTT1, GSTP1</italic>, and <italic>CYP1A1</italic> genotypes and risk of head and neck cancer</article-title><source><italic>Cancer Epidemiology Biomarkers &#x00026; Prevention</italic></source><year>2003</year><volume>12</volume><issue>12</issue><fpage>1509</fpage><lpage>1517</lpage></citation></ref><ref id="B48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Varela-Lema</surname><given-names>L</given-names></name><name><surname>Taioli</surname><given-names>E</given-names></name><name><surname>Ruano-Ravina</surname><given-names>A</given-names></name><etal/></person-group><article-title>Meta-analysis and pooled analysis  of GSTM1 and CYP1A1 polymorphisms and oral and pharyngeal cancers: a HuGE-GSEC review</article-title><source><italic>Genetics in Medicine</italic></source><year>2008</year><volume>10</volume><issue>6</issue><fpage>369</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">18496222</pub-id></citation></ref><ref id="B49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Soya</surname><given-names>SS</given-names></name><name><surname>Vinod</surname><given-names>T</given-names></name><name><surname>Reddy</surname><given-names>KS</given-names></name><name><surname>Gopalakrishnan</surname><given-names>S</given-names></name><name><surname>Adithan</surname><given-names>C</given-names></name></person-group><article-title>Genetic polymorphisms of glutathione-<italic>S</italic>-transferase genes (<italic>GSTM1, GSTT1</italic> and <italic>GSTP1</italic>) and upper aerodigestive tract cancer risk among smokers, tobacco chewers and alcoholics in an Indian population</article-title><source><italic>European Journal of Cancer</italic></source><year>2007</year><volume>43</volume><issue>18</issue><fpage>2698</fpage><lpage>2706</lpage><pub-id pub-id-type="pmid">17707637</pub-id></citation></ref><ref id="B50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sikdar</surname><given-names>N</given-names></name><name><surname>Paul</surname><given-names>RR</given-names></name><name><surname>Roy</surname><given-names>B</given-names></name></person-group><article-title>Glutathione <italic>S</italic>-transferase <italic>M3 (A/A)</italic> genotype as a risk factor for oral cancer and leukoplakia among Indian tobacco smokers</article-title><source><italic>International Journal of Cancer</italic></source><year>2004</year><volume>109</volume><issue>1</issue><fpage>95</fpage><lpage>101</lpage></citation></ref><ref id="B51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buch</surname><given-names>SC</given-names></name><name><surname>Notani</surname><given-names>PN</given-names></name><name><surname>Bhisey</surname><given-names>RA</given-names></name></person-group><article-title>Polymorphism at <italic>GSTM1, GSTM3</italic> and <italic>GSTT1</italic> gene loci and susceptibility to oral cancer in an Indian population</article-title><source><italic>Carcinogenesis</italic></source><year>2002</year><volume>23</volume><issue>5</issue><fpage>803</fpage><lpage>807</lpage><pub-id pub-id-type="pmid">12016153</pub-id></citation></ref><ref id="B52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sreelekha</surname><given-names>TT</given-names></name><name><surname>Ramadas</surname><given-names>K</given-names></name><name><surname>Pandey</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Nalinakumari</surname><given-names>KR</given-names></name><name><surname>Pillai</surname><given-names>MR</given-names></name></person-group><article-title>Genetic polymorphism of <italic>CYP1A1, GSTM1</italic> and <italic>GSTT1</italic> genes in Indian oral cancer</article-title><source><italic>Oral Oncology</italic></source><year>2001</year><volume>37</volume><issue>7</issue><fpage>593</fpage><lpage>598</lpage><pub-id pub-id-type="pmid">11564581</pub-id></citation></ref><ref id="B53"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gatt&#x000e1;</surname><given-names>GJF</given-names></name><name><surname>de Carvalho</surname><given-names>MB</given-names></name><name><surname>Siraque</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Genetic polymorphisms of <italic>CYP1A1, CYP2E1, GSTM1</italic>, and <italic>GSTT1</italic> associated with head and neck cancer</article-title><source><italic>Head &#x00026; Neck</italic></source><year>2006</year><volume>28</volume><issue>9</issue><fpage>819</fpage><lpage>826</lpage><pub-id pub-id-type="pmid">16721740</pub-id></citation></ref><ref id="B54"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>H</given-names></name><name><surname>Hou</surname><given-names>L</given-names></name><name><surname>Shields</surname><given-names>PG</given-names></name><etal/></person-group><article-title>Metabolic polymoryphisms, smoking, and oral cancer in Puerto Rico</article-title><source><italic>Oncology Research</italic></source><year>2003</year><volume>14</volume><issue>6</issue><fpage>315</fpage><lpage>320</lpage><pub-id pub-id-type="pmid">15206494</pub-id></citation></ref><ref id="B55"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drummond</surname><given-names>SN</given-names></name><name><surname>De Marco</surname><given-names>L</given-names></name><name><surname>Noronha</surname><given-names>JCM</given-names></name><name><surname>Gomez</surname><given-names>RS</given-names></name></person-group><article-title>GSTM1 polymorphism and oral squamous cell carcinoma</article-title><source><italic>Oral Oncology</italic></source><year>2004</year><volume>40</volume><issue>1</issue><fpage>52</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">14662415</pub-id></citation></ref><ref id="B56"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kietthubthew</surname><given-names>S</given-names></name><name><surname>Sriplung</surname><given-names>H</given-names></name><name><surname>Au</surname><given-names>WW</given-names></name></person-group><article-title>Genetic and environmental interactions on oral cancer in Southern Thailand</article-title><source><italic>Environmental and Molecular Mutagenesis</italic></source><year>2001</year><volume>37</volume><issue>2</issue><fpage>111</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">11246217</pub-id></citation></ref><ref id="B57"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Izumo</surname><given-names>T</given-names></name><name><surname>Amagasa</surname><given-names>T</given-names></name></person-group><article-title>Genetic polymorphism of drug-metabolizing enzymes and susceptibility to oral cancer</article-title><source><italic>Carcinogenesis</italic></source><year>1999</year><volume>20</volume><issue>10</issue><fpage>1927</fpage><lpage>1931</lpage><pub-id pub-id-type="pmid">10506106</pub-id></citation></ref><ref id="B58"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Izumo</surname><given-names>T</given-names></name><name><surname>Amagasa</surname><given-names>T</given-names></name></person-group><article-title>Genetically high susceptibility to oral squamous cell carcinoma in terms of combined genotyping of <italic>CYP1A1</italic> and <italic>GSTM1</italic> genes</article-title><source><italic>Oral Oncology</italic></source><year>2000</year><volume>36</volume><issue>3</issue><fpage>267</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">10793329</pub-id></citation></ref><ref id="B59"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nomura</surname><given-names>T</given-names></name><name><surname>Noma</surname><given-names>H</given-names></name><name><surname>Shibahara</surname><given-names>T</given-names></name><name><surname>Yokoyama</surname><given-names>A</given-names></name><name><surname>Muramatusu</surname><given-names>T</given-names></name><name><surname>Ohmori</surname><given-names>T</given-names></name></person-group><article-title>Aldehyde dehydrogenase 2 and glutathione <italic>S</italic>-transferase M1 polymorphisms in relation to the risk for oral cancer in Japanese drinkers</article-title><source><italic>Oral Oncology</italic></source><year>2000</year><volume>36</volume><issue>1</issue><fpage>42</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">10889918</pub-id></citation></ref><ref id="B60"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kihara</surname><given-names>M</given-names></name><name><surname>Kihara</surname><given-names>M</given-names></name><name><surname>Kubota</surname><given-names>A</given-names></name><name><surname>Furukawa</surname><given-names>M</given-names></name><name><surname>Kimura</surname><given-names>H</given-names></name></person-group><article-title>						<italic>GSTM1</italic> gene polymorphism as a possible marker for susceptibility to head and neck cancers among Japanese smokers</article-title><source><italic>Cancer Letters</italic></source><year>1997</year><volume>112</volume><issue>2</issue><fpage>257</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">9066737</pub-id></citation></ref><ref id="B61"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marques</surname><given-names>CFS</given-names></name><name><surname>Koifman</surname><given-names>S</given-names></name><name><surname>Koifman</surname><given-names>RJ</given-names></name><name><surname>Boffetta</surname><given-names>P</given-names></name><name><surname>Brennan</surname><given-names>P</given-names></name><name><surname>Hatagima</surname><given-names>A</given-names></name></person-group><article-title>Influence of <italic>CYP1A1, CYP2E1, GSTM3</italic> and <italic>NAT2</italic> genetic polymorphisms in oral cancer susceptibility: results from a case-control study in Rio de Janeiro</article-title><source><italic>Oral Oncology</italic></source><year>2006</year><volume>42</volume><issue>6</issue><fpage>632</fpage><lpage>637</lpage><pub-id pub-id-type="pmid">16488179</pub-id></citation></ref><ref id="B62"><label>62</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>IARC (International Agency for Research on Cancer)</surname></name></person-group><source><italic>Alcohol Drinking</italic></source><year>1998</year><volume>44</volume><publisher-loc>Lyon, France</publisher-loc><publisher-name>IARC Press</publisher-name><series>IARC Monographs on the Evaluation of Carcinogenic Risks to Human</series></citation></ref><ref id="B63"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ristow</surname><given-names>H</given-names></name><name><surname>Obe</surname><given-names>G</given-names></name></person-group><article-title>Acetaldehyde induces cross-links in DNA and causes sister-chromatid exchanges in human cells</article-title><source><italic>Mutation Research</italic></source><year>1978</year><volume>58</volume><issue>1</issue><fpage>115</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">714076</pub-id></citation></ref><ref id="B64"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Howie</surname><given-names>NM</given-names></name><name><surname>Trigkas</surname><given-names>TK</given-names></name><name><surname>Cruchley</surname><given-names>AT</given-names></name><name><surname>Wertz</surname><given-names>PW</given-names></name><name><surname>Squier</surname><given-names>CA</given-names></name><name><surname>Williams</surname><given-names>DM</given-names></name></person-group><article-title>Short-term exposure to alcohol increases the permeability of human oral mucosa</article-title><source><italic>Oral Diseases</italic></source><year>2001</year><volume>7</volume><issue>6</issue><fpage>349</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">11834098</pub-id></citation></ref><ref id="B65"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruano-Ravina</surname><given-names>A</given-names></name><name><surname>Figueiras</surname><given-names>A</given-names></name><name><surname>Barros-Dios</surname><given-names>JM</given-names></name></person-group><article-title>Type of wine and risk of lung cancer: a case-control study in Spain</article-title><source><italic>Thorax</italic></source><year>2004</year><volume>59</volume><issue>11</issue><fpage>981</fpage><lpage>985</lpage><pub-id pub-id-type="pmid">15516476</pub-id></citation></ref><ref id="B66"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>RJ</given-names></name><name><surname>Boffetta</surname><given-names>P</given-names></name><name><surname>Brockm&#x000f6;ller</surname><given-names>J</given-names></name><etal/></person-group><article-title>CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis</article-title><source><italic>Carcinogenesis</italic></source><year>2003</year><volume>24</volume><issue>5</issue><fpage>875</fpage><lpage>882</lpage><pub-id pub-id-type="pmid">12771031</pub-id></citation></ref><ref id="B67"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taioli</surname><given-names>E</given-names></name><name><surname>Gaspari</surname><given-names>L</given-names></name><name><surname>Benhamou</surname><given-names>S</given-names></name><etal/></person-group><article-title>Polymorphisms in CYP1A1, GSTM1, GSTT1 and lung cancer below the age of 45 years</article-title><source><italic>International Journal of Epidemiology</italic></source><year>2003</year><volume>32</volume><issue>1</issue><fpage>60</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">12690010</pub-id></citation></ref><ref id="B68"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vineis</surname><given-names>P</given-names></name><name><surname>Veglia</surname><given-names>F</given-names></name><name><surname>Anttila</surname><given-names>S</given-names></name><etal/></person-group><article-title>CYP1A1, GSTM1 and GSTT1 polymorphisms and lung cancer: a pooled analysis of gene-gene interactions</article-title><source><italic>Biomarkers</italic></source><year>2004</year><volume>9</volume><issue>3</issue><fpage>298</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">15764294</pub-id></citation></ref><ref id="B69"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crofts</surname><given-names>F</given-names></name><name><surname>Taioli</surname><given-names>E</given-names></name><name><surname>Trachman</surname><given-names>J</given-names></name><etal/></person-group><article-title>Functional significance of different human CYPlAl genotypes</article-title><source><italic>Carcinogenesis</italic></source><year>1994</year><volume>15</volume><issue>12</issue><fpage>2961</fpage><lpage>2963</lpage><pub-id pub-id-type="pmid">8001264</pub-id></citation></ref><ref id="B70"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rojas</surname><given-names>M</given-names></name><name><surname>Alexandrov</surname><given-names>K</given-names></name><name><surname>Cascorbi</surname><given-names>I</given-names></name><etal/></person-group><article-title>High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/MspI-GSTM1*0/*0 genotypes</article-title><source><italic>Pharmacogenetics</italic></source><year>1998</year><volume>8</volume><issue>2</issue><fpage>109</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">10022748</pub-id></citation></ref></ref-list></back><floats-wrap><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>Description of the study individuals.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"> Variable considered </th><th align="center" rowspan="1" colspan="1"> Cases </th><th align="center" rowspan="1" colspan="1"> Controls </th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"> Age (mean, IC95%) </td><td align="center" rowspan="1" colspan="1">55.0 (52.7&#x02013;57.3)</td><td align="center" rowspan="1" colspan="1">59.4 (57.0&#x02013;61.8)</td></tr><tr><td align="center" colspan="3" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Cancer location </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="3" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Oral</td><td align="center" rowspan="1" colspan="1">53 (57.6%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Pharyngeal</td><td align="center" rowspan="1" colspan="1">39 (42.4%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="3" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Cigarette smoking </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="3" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Never smoker</td><td align="center" rowspan="1" colspan="1">2 (2.2%)</td><td align="center" rowspan="1" colspan="1">49 (37.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Former smoker</td><td align="center" rowspan="1" colspan="1">17 (18.5%)</td><td align="center" rowspan="1" colspan="1">42 (32.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Current smoker</td><td align="center" rowspan="1" colspan="1">73 (79.3%)</td><td align="center" rowspan="1" colspan="1">39 (30%)</td></tr><tr><td align="center" colspan="3" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Tobacco consumption (pack-years) </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="3" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Percentil 25</td><td align="center" rowspan="1" colspan="1">33.0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Percentil 50</td><td align="center" rowspan="1" colspan="1">46.5</td><td align="center" rowspan="1" colspan="1">9.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Percentil 75</td><td align="center" rowspan="1" colspan="1">67.5</td><td align="center" rowspan="1" colspan="1">43.8</td></tr><tr><td align="center" colspan="3" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Drinking habit </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="3" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">No alcohol drinking</td><td align="center" rowspan="1" colspan="1">2 (2.2%)</td><td align="center" rowspan="1" colspan="1">20 (15.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Light drinker (&#x02264;2 glasses of wine/beers or 2 licors a day) (0&#x02013;280 gm/week)</td><td align="center" rowspan="1" colspan="1">6 (6.5%)</td><td align="center" rowspan="1" colspan="1">50 (38.5%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Moderate drinkers (3&#x02013;6 drinks/day) (281&#x02013;840 g/week)</td><td align="center" rowspan="1" colspan="1">41 (44.6%)</td><td align="center" rowspan="1" colspan="1">46 (35.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Heavy drinkers (&#x0003e;6 drinks/day) (&#x0003e;840 gm/week)</td><td align="center" rowspan="1" colspan="1">43 (46.7%)</td><td align="center" rowspan="1" colspan="1">14 (10.8%)</td></tr><tr><td align="center" colspan="3" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Alcohol consumption gm/week </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="3" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Percentil 25</td><td align="center" rowspan="1" colspan="1">290</td><td align="center" rowspan="1" colspan="1">70</td></tr><tr><td align="left" rowspan="1" colspan="1">Percentil 50</td><td align="center" rowspan="1" colspan="1">560</td><td align="center" rowspan="1" colspan="1">145</td></tr><tr><td align="left" rowspan="1" colspan="1">Percentil 75</td><td align="center" rowspan="1" colspan="1">840</td><td align="center" rowspan="1" colspan="1">300</td></tr><tr><td align="center" colspan="3" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> CYP1A1 </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="3" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Wild type (Ile/Ile)</td><td align="center" rowspan="1" colspan="1">64 (97%)</td><td align="center" rowspan="1" colspan="1">90 (97.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Mutation (Ile/Val, Val/Val)</td><td align="center" rowspan="1" colspan="1">2 (3%)</td><td align="center" rowspan="1" colspan="1">2 (2.2%)</td></tr><tr><td align="center" colspan="3" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> mEH (139 Arg &#x02192; His) </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="3" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Arg/Arg</td><td align="center" rowspan="1" colspan="1">63 (68.5%)</td><td align="center" rowspan="1" colspan="1">88 (67.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Arg/His</td><td align="center" rowspan="1" colspan="1">25 (27.2%)</td><td align="center" rowspan="1" colspan="1">41 (31.5%)</td></tr><tr><td align="left" rowspan="1" colspan="1">His/His</td><td align="center" rowspan="1" colspan="1">4 (4.3%)</td><td align="center" rowspan="1" colspan="1">1 (0.8%)</td></tr><tr><td align="center" colspan="3" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> GSTM1 </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="3" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Present (GSTM1 +)</td><td align="center" rowspan="1" colspan="1">45 (48.9%)</td><td align="center" rowspan="1" colspan="1">68 (52.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Absent (GSTM1 &#x02212;)</td><td align="center" rowspan="1" colspan="1">47 (51.1%)</td><td align="center" rowspan="1" colspan="1">62 (47.7%)</td></tr><tr><td align="center" colspan="3" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Total </td><td align="center" rowspan="1" colspan="1">92</td><td align="center" rowspan="1" colspan="1">130</td></tr></tbody></table></table-wrap><table-wrap id="tab2" position="float"><label>Table 2</label><caption><p>Risks for oral and pharyngeal cancers associated withpolymorphisms in genes CYP1A1, mEH, and GSTM1.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"> Gene </th><th align="center" rowspan="1" colspan="1"> Cases </th><th align="center" rowspan="1" colspan="1"> Controls </th><th align="center" rowspan="1" colspan="1"> OR crude (CI 95%)*</th><th align="center" rowspan="1" colspan="1"> OR adjusted (CI 95%)<sup>+</sup></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"> All cancers  </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">CYP1A1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">No mutated</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Mutated</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.72 (0.10&#x02013;5.28)</td><td align="center" rowspan="1" colspan="1">1.68 (0.18&#x02013;15.70)</td></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> mEH (139His &#x02192; Arg) </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">His/His</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">His/Arg</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.95 (0.52&#x02013;1.75)</td><td align="center" rowspan="1" colspan="1">0.81 (0.38&#x02013;1.71)</td></tr><tr><td align="left" rowspan="1" colspan="1">Arg/arg</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">4.30 (0.46&#x02013;40.07)</td><td align="center" rowspan="1" colspan="1">4.45 (0.39&#x02013;50.45)</td></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> GSTM1 </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Present</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Absent</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1.16 (0.73&#x02013;1.99)</td><td align="center" rowspan="1" colspan="1">1.25 (0.65&#x02013;2.40)</td></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Oral cancer </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> CYP1A1 </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">No mutated</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">64 (97%)</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Mutated</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">2 (3%)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> mEH (139His &#x02192; Arg) </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">His/His</td><td align="center" rowspan="1" colspan="1">39 (73,6%)</td><td align="center" rowspan="1" colspan="1">88 (67,7%)</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">His/Arg</td><td align="center" rowspan="1" colspan="1">12 (22,6%)</td><td align="center" rowspan="1" colspan="1">41 (31,5%)</td><td align="center" rowspan="1" colspan="1">0.74 (0.34&#x02013;1.58)</td><td align="center" rowspan="1" colspan="1">0.54 (0.21&#x02013;1.41)</td></tr><tr><td align="left" rowspan="1" colspan="1">Arg/arg</td><td align="center" rowspan="1" colspan="1">2 (3,8%)</td><td align="center" rowspan="1" colspan="1">1 (0,8%)</td><td align="center" rowspan="1" colspan="1">3.44 (0.29&#x02013;40.16)</td><td align="center" rowspan="1" colspan="1">4.32 (0.32&#x02013;58.63)</td></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> GSTM1 </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Present</td><td align="center" rowspan="1" colspan="1">26 (49,1%)</td><td align="center" rowspan="1" colspan="1">68 (52,3%)</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Absent</td><td align="center" rowspan="1" colspan="1">27 (50,9%)</td><td align="center" rowspan="1" colspan="1">62 (47,7%)</td><td align="center" rowspan="1" colspan="1">1.14 (0.60&#x02013;2.19)</td><td align="center" rowspan="1" colspan="1">1.20 (0.56&#x02013;2.18)</td></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> Pharyngeal cancer </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> CYP1A1 </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">No mutated</td><td align="center" rowspan="1" colspan="1">37 (94,9%)</td><td align="center" rowspan="1" colspan="1">64 (97%)</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Mutated</td><td align="center" rowspan="1" colspan="1">2 (5,1%)</td><td align="center" rowspan="1" colspan="1">2 (3%)</td><td align="center" rowspan="1" colspan="1">1.74 (0.23&#x02013;12.92)</td><td align="center" rowspan="1" colspan="1">4.06 (0.43&#x02013;38.24)</td></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> mEH (139His &#x02192; Arg) </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">His/His</td><td align="center" rowspan="1" colspan="1">24 (61,5%)</td><td align="center" rowspan="1" colspan="1">88 (67,7%)</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">His/Arg</td><td align="center" rowspan="1" colspan="1">13 (33,3%)</td><td align="center" rowspan="1" colspan="1">41 (31,5%)</td><td align="center" rowspan="1" colspan="1">1.27 (0.58&#x02013;2.80)</td><td align="center" rowspan="1" colspan="1">1.07 (0.42&#x02013;2.71)</td></tr><tr><td align="left" rowspan="1" colspan="1">Arg/arg</td><td align="center" rowspan="1" colspan="1">2 (5,2%)</td><td align="center" rowspan="1" colspan="1">1 (0,8%)</td><td align="center" rowspan="1" colspan="1">5.58 (0.47&#x02013;66.10)</td><td align="center" rowspan="1" colspan="1">5.74 (0.34&#x02013;97.71)</td></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> GSTM1 </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Present</td><td align="center" rowspan="1" colspan="1">19 (48,7%)</td><td align="center" rowspan="1" colspan="1">68 (52,3%)</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Absent</td><td align="center" rowspan="1" colspan="1">20 (51,3%)</td><td align="center" rowspan="1" colspan="1">62 (47,7%)</td><td align="center" rowspan="1" colspan="1">1.20 (0.58&#x02013;2.48)</td><td align="center" rowspan="1" colspan="1">1.44 (0.61&#x02013;3.37)</td></tr></tbody></table><table-wrap-foot><fn><p>*Adjusted for age.</p><p>						<sup>+</sup>Adjusted for age, smoking, and alcohol intake.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab3" position="float"><label>Table 3</label><caption><p>Risks for the different polymorphisms broken down bysmoking categories.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"> Genetic polymorphism </th><th align="center" rowspan="1" colspan="1"> Cases </th><th align="center" rowspan="1" colspan="1"> Controls </th><th align="center" rowspan="1" colspan="1"> OR crude </th><th align="center" rowspan="1" colspan="1"> OR adjusted </th></tr></thead><tbody><tr><td align="center" colspan="5" rowspan="1"> Light/moderate smokers (&#x02264;35 pack-years) </td></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> CYP1A1 </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">No mutated</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">41</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Mutated</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0.76 (0.06&#x02013;8.90)</td><td align="center" rowspan="1" colspan="1">1.12 (0.09&#x02013;13.94)</td></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> mEH (139His &#x02192; Arg) </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">His/His</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">1,00</td></tr><tr><td align="left" rowspan="1" colspan="1">His/Arg</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">1.06 (0.40&#x02013;2.78)</td><td align="center" rowspan="1" colspan="1">1.08 (0.37&#x02013;3.13)</td></tr><tr><td align="left" rowspan="1" colspan="1">Arg/arg</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1.91 (0.11&#x02013;33.10)</td><td align="center" rowspan="1" colspan="1">2.82 (0.15&#x02013;52.41)</td></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> GSTM1 </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Present</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Absent</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">0.74 (0.31&#x02013;1.76)</td><td align="center" rowspan="1" colspan="1">0.88 (0.34&#x02013;2.34)</td></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="center" colspan="5" rowspan="1"> Heavy smokers (&#x0003e;35 pack-years) </td></tr><tr><td align="center" colspan="6" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> CYP1A1 </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">No mutated</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">62</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Mutated</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> mEH (139His &#x02192; Arg) </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">His/His</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">His/Arg</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">0.94 (0.39&#x02013;2.26)</td><td align="center" rowspan="1" colspan="1">0.68 (0.25&#x02013;1.86)</td></tr><tr><td align="left" rowspan="1" colspan="1">Arg/arg</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> GSTM1 </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Present</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Absent</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">1.50 (0.67&#x02013;1.33)</td><td align="center" rowspan="1" colspan="1">1.40 (0.57&#x02013;3.43)</td></tr></tbody></table></table-wrap><table-wrap id="tab4" position="float"><label>Table 4</label><caption><p>Risks for the different polymorphisms broken down byalcohol intake.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"> Genetic polymorphism </th><th align="center" rowspan="1" colspan="1"> Cases </th><th align="center" rowspan="1" colspan="1"> Controls </th><th align="center" rowspan="1" colspan="1"> OR crude </th><th align="center" rowspan="1" colspan="1"> OR adjusted </th></tr></thead><tbody><tr><td align="center" colspan="5" rowspan="1"> Light drinkers (&#x02264;280 gm alcohol/week) </td></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> CYP1A1 </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">No mutated</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Mutated</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> mEH (139His &#x02192; Arg) </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">His/His</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">His/Arg</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">0.57 (0.19&#x02013;1.72)</td><td align="center" rowspan="1" colspan="1">0.71 (0.22&#x02013;2.24)</td></tr><tr><td align="left" rowspan="1" colspan="1">Arg/arg</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> GSTM1 </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Present</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Absent</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1">1.55 (0.62&#x02013;3.88)</td><td align="center" rowspan="1" colspan="1">1.97 (0.73&#x02013;5.35)</td></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="center" colspan="5" rowspan="1"> Moderate/heavy drinkers (&#x0003e;280 gm alcohol/week) </td></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> CYP1A1 </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">No mutated</td><td align="center" rowspan="1" colspan="1">67</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Mutated</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> mEH (139His &#x02192; Arg) </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">His/His</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">His/Arg</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">1.28 (0.50&#x02013;3.31)</td><td align="center" rowspan="1" colspan="1">0.83 (0.30&#x02013;2.30)</td></tr><tr><td align="left" rowspan="1" colspan="1">Arg/arg</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"> GSTM1 </td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="5" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Present</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Absent</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">0.79 (0.34&#x02013;1.86)</td><td align="center" rowspan="1" colspan="1">0.69 (0.28&#x02013;1.72)</td></tr></tbody></table></table-wrap><table-wrap id="tab5" position="float"><label>Table 5</label><caption><p>Combinationof polymorphisms mEH and GSTM1 and risk of oropharyngeal cancer.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"> Combination of genetic polymorphisms </th><th align="center" rowspan="1" colspan="1"> Cases </th><th align="center" rowspan="1" colspan="1"> Controls </th><th align="center" rowspan="1" colspan="1"> OR crude </th><th align="center" rowspan="1" colspan="1"> OR adjusted </th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"> mEH (Arg/Arg)/GSTM1 present </td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1"> mEH (Arg/Arg)/GSTM1 absent </td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">1.22 (0.63&#x02013;2.36)</td><td align="center" rowspan="1" colspan="1">1.45 (0.66&#x02013;3.17)</td></tr><tr><td align="left" rowspan="1" colspan="1"> mEH mutated/GSTM1 present </td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">1.15 (0.50&#x02013;2.65)</td><td align="center" rowspan="1" colspan="1">1,19 (0.43&#x02013;3.27)</td></tr><tr><td align="left" rowspan="1" colspan="1"> mEH mutated/GSTM1 absent </td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">1.18 (0.52&#x02013;2.66)</td><td align="center" rowspan="1" colspan="1">1.07 (0.39&#x02013;2.92).</td></tr></tbody></table></table-wrap></floats-wrap></article>